Update on antiphospholipid syndrome.
This review addresses new clinical issues (revealed at the 2006 Sydney update of the 1999 Sapporo Classification criteria; cardiac, renal, and multiple sclerosis-like disease; catastrophic syndrome), mechanisms of action of antiphospholipid antibody (very likely complement mediated), current therapies (moderate dose warfarin recommended for prophylaxis, aspirin not recommended for primary prophylaxis), and potential new therapies.
Lockshin
Michael D
MD
Weill Medical College, Cornell University, USA. lockshinm@hss.edu
D017152:Antibodies, Antiphospholipid / Q000097:blood; D000925:Anticoagulants / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D001241:Aspirin / Q000627:therapeutic use; D001777:Blood Coagulation; D003165:Complement System Proteins / Q000378:metabolism; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D013927:Thrombosis / Q000097:blood / Q000276:immunology / Q000517:prevention & control; D014859:Warfarin / Q000627:therapeutic use
D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D003165:Complement System Proteins; D001241:Aspirin